Adjunctive and alternative approaches to current reperfusion therapy

Stroke

Volumn 43, Issue 2, 2012, Pages 591-598

  Barreto, Andrew D ^a   Alexandrov, Andrei V ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

acute stroke; adjunctive treatment; endovascular treatment; reperfusion; thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANCROD; ARGATROBAN; DESMOTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLASMIN; RETEPLASE; TENECTEPLASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL AORTA; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTERY CATHETERIZATION; ARTERY OCCLUSION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN ARTERY RECANALIZATION; BRAIN BLOOD FLOW; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN REPERFUSION; COUNTERPULSATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLECTOMY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; INTERACTIVE VENTILATORY SUPPORT; LOW DRUG DOSE; MICROBUBBLE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; SONOTHROMBOLYSIS; SPHENOPALATINE GANGLION STIMULATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; ULTRASOUND THERAPY; UNSPECIFIED SIDE EFFECT;

ASPIRIN; ELECTRIC STIMULATION THERAPY; ENDOVASCULAR PROCEDURES; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REPERFUSION INJURY; STROKE; THROMBIN; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONIC THERAPY;

EID: 84856499792     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.617902     Document Type: Article

References (57)

1. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
2. Lindsay P, Bayley M, McDonald A, Graham ID, Warner G, Phillips S. Toward a more effective approach to stroke: Canadian best practice recommendations for stroke care. CMAJ. 2008;178:1418-1425. (Pubitemid 351775717)
3. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
4. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38: 948-954. (Pubitemid 46568457)
5. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicenter, randomized study of Argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: Myocardial Infarction with Novastan and tPA (MINT) study. J Am Coll Cardiol. 1999;33:1879-1885.
6. Kawai H, Umemura K, Nakashima M. Effect of Argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J Pharmacol. 1995;69:143-148.
7. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res. 1990;67:1552-1561.
8. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, et al. Extension of the therapeutic window for recombinant tissue plasminogen activator with Argatroban in a rat model of embolic stroke. Stroke. 2001;32:2635-2640. (Pubitemid 33055318)
9. LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): A randomized, placebo-controlled safety study. Stroke. 2004;35:1677-1682. (Pubitemid 38823646)
10. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:2170-2178. (Pubitemid 39507629)
11. Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006;63:1057-1062. (Pubitemid 44232309)
12. Mikulik R, Dufek M, Goldemund D, Reif M. A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke. Eur J Neurol. 2006;13:1106-1111. (Pubitemid 44434316)
13. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2004;110:588-636.
14. Basinski A, Naylor CD. Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for synergy. J Clin Epidemiol. 1991; 44:1085-1096.
15. Zinkstok SM, Vermeulen M, Stam J, de Haan RJ, Roos YB. Antiplatelet therapy in combination with rtPA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial. Cerebrovasc Dis. 2010;29:79-81.
16. Zinkstok SM, Vermeulen M, Stam J, de Haan RJ, Roos YB. A randomised controlled trial of antiplatelet therapy in combination with rtPA thrombolysis in ischemic stroke: rationale and design of the ARTIS-trial. Trials. 2010;11:51.
17. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, doseranging trial. IMPACT-AMI investigators. Circulation. 1997;95: 846-854. (Pubitemid 27091524)
18. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905-1914. (Pubitemid 32568330)
19. Siebler M. Safety of tirofiban in acute ischemic stroke [Abstract]. European Stroke Conference, Brussels, Belgium, May 16-19, 2006.
20. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international Phase III trial: Abciximab in emergency treatment of stroke trial (ABESTT-II). Stroke. 2008;39: 87-99.
21. Torgano G, Zecca B, Monzani V, Maestroni A, Rossi P, Cazzaniga M, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: A double-blind randomized trial. Cerebrovasc Dis. 2010;29:275-281.
22. Mousa SA. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography. Blood Coagul Fibrinolysis. 2007;18:55-60. (Pubitemid 46006275)
23. Nakada MT, Montgomery MO, Nedelman MA, Guerrero JL, Cohen SA, Barnathan ES, et al. Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: Addition of abciximab results in improved vessel reperfusion. J Vasc Interv Radiol. 2004;15:169-176. (Pubitemid 38248918)
24. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al. The combined approach to lysis utilizing eptifibatide and rtPA in acute ischemic stroke: the CLEAR stroke trial. Stroke. 2008;39:3268-3276.
25. University of Cincinnati. Study of the combination therapy of rt-PA and eptifibatide to treat acute ischemic stroke (CLEAR-ER). www.Clinical Trials.gov. Bethesda, MD: National Library of Medicine; 2000 [cited February 22, 2011]. Available at: http://clinicaltrials.gov/show/NCT
26. -00894803. NLM Identifier: NCT00894803.
27. Warach S. Reopro retavase reperfusion of stroke safety study-imaging evaluation. International Stroke Conference-late breaking abstracts, Kissimmee, Florida, February 15-18, 2006.
28. Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a Phase II clinical trial. Stroke. 2005;36:1441-1446. (Pubitemid 40967509)
29. Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, et al. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke. 2006;37:425-429. (Pubitemid 43731999)
30. Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol. 2009;66:28-38.
31. Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: A comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke. 2010;41:280-287.
32. The University of Texas Health Science Center, Houston. Combined lysis of thrombus in brain ischemia with transcranial ultrasound and systemic tPA-hands-free. A Phase I/II pilot safety trial. www.ClinicalTrials.gov. Bethesda, MD: National Library of Medicine; 2000 [cited February 22, 2011]. Available at: http://clinicaltrials.gov/show/NCT01240356. NLM Identifier: NCT01240356.
33. Cerevast Therapeutics. A randomized, active controlled, double-blinded trial of the combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator (tPA) for emergent revascularization (CLOTBUSTER) in acute ischemic stroke. www.ClinicalTrials.gov. Bethesda, MD: National Library of Medicine; 2000 [cited September 22, 2011]. Available at: http://clinicaltrials. gov/show/NCT01098981. NLM Identifier: NCT01098981.
34. Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 1994;25:2072-2078.
35. Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM. A pilot doseescalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005;36:607-612. (Pubitemid 40344164)
36. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIb/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41:707-711.
37. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The desmoteplase in acute ischemic stroke trial (DIAS): A Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73. (Pubitemid 40054177)
38. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231. (Pubitemid 43731867)
39. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141-150.
40. Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. Thrombolysis with plasmin: implications for stroke treatment. Stroke. 2010;41:S45-S49.
41. Ancrod for the treatment of acute ischemic brain infarction. The ancrod stroke study investigators. Stroke. 1994;25:1755-1759.
42. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: A randomized controlled trial. Stroke treatment with ancrod trial. JAMA. 2000;283:2395-2403. (Pubitemid 30257538)
43. Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener HC, Howard G, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke. 2009;40:3796-3803.
44. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM. Intravenous ancrod for acute ischaemic stroke in the European stroke treatment with ancrod trial: A randomised controlled trial. Lancet. 2006;368:1871-1878. (Pubitemid 44794528)
45. Leifer D, Bravata DM, Connors JJ III, Hinchey JA, Jauch EC, Johnston SC, et al. Metrics for measuring quality of care in comprehensive stroke centers: detailed follow-up to brain attack coalition comprehensive stroke center recommendations: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:849-877.
46. Khatri P, Abruzzo T, Yeatts SD, Nichols C, Broderick JP, Tomsick TA. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology. 2009;73:1066-1072.
47. Levy EI, Siddiqui AH, Crumlish A, Snyder KV, Hauck EF, Fiorella DJ, et al. First food and drug administration-approved prospective trial of primary intracranial stenting for acute stroke: SARIS (Stent-Assisted Recanalization in Acute Ischemic Stroke). Stroke. 2009;40:3552-3556.
48. Ribo M, Molina CA, Alvarez B, Rubiera M, Alvarez-Sabin J, Matas M. Intra-arterial administration of microbubbles and continuous 2-MHz ultrasound insonation to enhance intra-arterial thrombolysis. J Neuroimaging. 2010;20:224-227.
49. Alexandrov AV, Tsivgoulis G, Rubiera M, Vadikolias K, Stamboulis E, Molina CA, et al. End-diastolic velocity increase predicts recanalization and neurological improvement in patients with ischemic stroke with proximal arterial occlusions receiving reperfusion therapies. Stroke. 2010; 41:948-952.
50. Alexandrov AW, Ribo M, Wong KS, Sugg RM, Garami Z, Jesurum JT, et al. Perfusion augmentation in acute stroke using mechanical counterpulsation-Phase IIa: effect of external counterpulsation on middle cerebral artery mean flow velocity in five healthy subjects. Stroke. 2008; 39:2760-2764.
51. Han JH, Leung TW, Lam WW, Soo YO, Alexandrov AW, Mok V, et al. Preliminary findings of external counterpulsation for ischemic stroke patient with large artery occlusive disease. Stroke. 2008;39:1340-1343. (Pubitemid 351440713)
52. Alexandrov AV, Nguyen HT, Rubiera M, Alexandrov AW, Zhao L, Heliopoulos I, et al. Prevalence and risk factors associated with reversed Robin Hood syndrome in acute ischemic stroke. Stroke. 2009;40: 2738-2742.
53. Palazzo P, Balucani C, Barlinn K, Tsivgoulis G, Zhang Y, Zhao L, et al. Association of reversed Robin Hood syndrome with risk of stroke recurrence. Neurology. 2010;75:2003-2008.
54. Barlinn K, Alexandrov AV. Sleep-disordered breathing and arterial blood flow steal represent linked therapeutic targets in cerebral ischaemia. Int J Stroke. 2011;6:40-41.
55. Tsivgoulis G, Zhang Y, Alexandrov AW, Harrigan MR, Sisson A, Zhao L, et al. Safety and tolerability of early noninvasive ventilatory correction using bilevel positive airway pressure in acute ischemic stroke. Stroke. 2011;42:1030-1034.
56. Toda N, Tanaka T, Ayajiki K, Okamura T. Cerebral vasodilatation induced by stimulation of the pterygopalatine ganglion and greater petrosal nerve in anesthetized monkeys. Neuroscience. 2000;96:393-398. (Pubitemid 30100420)
57. BrainsGate. Implant for augmentation of cerebral blood flow trial, effectiveness and safety in a 24 hour window (impact-24). www.ClinicalTrials. gov. Bethesda, MD: National Library of Medicine; 2000 [cited September 22, 2011]. Available at: http://clinicaltrials.gov/show/NCT00826059. NLM Identifier: NCT00826059.